Myrtelle Announces Presentation of Positive 6-month Post-Treatment Data in Its First-in-Human Clinical Study of rAAV-Olig001-ASPA Gene Therapy in Canavan Disease at the American Society of Gene and Cell Therapy 26th Annual Meeting
Wakefield, Mass., May, 16th, 2023 – Myrtelle Inc. (“Myrtelle” or the “Company”), a gene therapy company focused on developing transformative treatments for neurodegenerative diseases…
Article Date
May 16, 2023
This article is featured on another website.
Go to article
January 15, 2026
Q&A with Sean A. MacDonald, Chief Executive Officer at Kainova Therapeutics
January 15, 2026
Q&A with Sean A. MacDonald, Chief Executive Officer at Kainova Therapeutics
January 29, 2026
Rescuing a Rare Disease Trial: Accelerating MRCT RA Submissions for a Taiwan Biotech Company
This case study highlights HiRO's effective intervention in accelerating the regulatory submission process for a…
January 29, 2026
Rescuing a Rare Disease Trial: Accelerating MRCT RA Submissions for a Taiwan Biotech Company
This case study highlights HiRO's effective intervention in accelerating the regulatory submission process for a…